Emboldened by technological advances and a deeper knowledge of glioblastoma, Merck, Kazia Therapeutics, CorriXR Therapeutics ...

Researchers discovered an unexpected link between zinc deficiency, the pro-inflammatory cytokine interleukin-13 (IL-13), and Acinetobacter baumannii lung infection and demonstrated that blocking IL-13 ...

Nov. 25, 2024 — It has been a year ago since bacteria from war-wounded at hospitals in Ukraine were analyzed. The study showed that some of the bacteria types had total resistance to antibiotics ...

Dietary zinc deficiency promotes lung infection by Acinetobacter baumannii bacteria—a leading cause of ventilator-associated ...

New research has shown that a lack of dietary zinc can boost the chances of a lung infection caused by Acinetobacter ...

An obvious next step in the development and growth of CAR T-cell therapies has been the jump to solid tumors. Because of ...

Bristol-Myers Squibb (BMS) has been steadily building its position in fibrotic diseases for some time, but accelerated its efforts this week with a $1.25 billion deal giving it the right to buy ...

The EMA has started a review of Leo Pharma’s interleukin-13 inhibitor tralokinumab as an antibody therapy for atopic dermatitis, a category that is currently dominated by Sanofi and Regeneron ...

Eli Lilly’s Ebglyss (lebrikizumab-lbkz) showed improvement in skin clearance and itch relief for most patients with ...

A new study published in the journal of Respiratory Medicine showed that patients with type 2 inflammation and chronic ...

Developed using Regeneron’s VelocImmune technology, Dupixent is a fully human monoclonal antibody that blocks the interleukin-4 (IL4) and interleukin-13 (IL13) signalling pathways. Regeneron and ...

Dupixent, which was invented using Regeneron's proprietary VelocImmune technology, is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 ...